Edition:
United Kingdom

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

24.37USD
13 Dec 2017
Change (% chg)

$0.79 (+3.35%)
Prev Close
$23.58
Open
$23.32
Day's High
$24.55
Day's Low
$23.23
Volume
341,540
Avg. Vol
375,922
52-wk High
$31.80
52-wk Low
$13.13

Latest Key Developments (Source: Significant Developments)

Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - ‍PRICING OF AN UNDERWRITTEN OFFERING OF 1.97 MILLION SHARES OF ITS COMMON STOCK​.  Full Article

Editas Medicine Announces Offering Of Common Stock
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Editas Medicine announces Q3 loss per share $0.64
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Editas Medicine Inc ::Editas Medicine announces third quarter 2017 results and update.Q3 loss per share $0.64.Q3 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.Editas Medicine Inc - ‍cash, cash equivalents, and marketable securities at Sept. 30, 2017, were $295.7 million, compared to $199.9 million at Sept. 30, 2016​.  Full Article

Flagship Ventures Fund reports a 9.4 percent passive stake in Editas Medicine as of Dec 31, 2016
Monday, 13 Feb 2017 

Editas Medicine Inc :Flagship Ventures Fund reports a 9.4 percent passive stake in Editas Medicine Inc as of Dec 31, 2016 - SEC filing.  Full Article

Editas Medicine announces Q2 2016 results
Tuesday, 9 Aug 2016 

Editas Medicine Inc : Editas Medicine announces second quarter 2016 results and update . Q2 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S . Q2 revenue view $2.4 million -- Thomson Reuters I/B/E/S . Q2 loss per share $0.54 .Q2 revenue $3.4 million.  Full Article

Adverum Biotechnologies and Editas Medicine announce collaboration
Tuesday, 9 Aug 2016 

Adverum Biotechnologies Inc : Editas will also pay an additional option exercise fee of $1 million for an exclusive license to Adverum's AAV vectors . Is eligible to get development, commercial milestone payments, royalties on any resulting commercialized Editas products . Adverum biotechnologies and Editas Medicine announce collaboration to explore delivery of genome editing medicines to eye .Editas will pay Adverum an upfront fee of $1 million.  Full Article

Editas Medicine Q1 loss per share $0.80
Monday, 16 May 2016 

Editas Medicine Inc : Editas medicine announces first quarter 2016 results and update .Q1 loss per share $0.80.  Full Article

Editas Medicine Inc announces closing of initial public offering
Monday, 8 Feb 2016 

Editas Medicine Inc:Closes its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share.Shares began trading on the NASDAQ Global Select Market on February 3, 2016.Morgan Stanley and J.P. Morgan acted as joint book-running managers for the offering.Cowen and Company acted as lead manager, and JMP Securities acted as co-manager for the offering.  Full Article

BRIEF-Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock

* EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK